Auhtors: Tseng CH
PMID: 30896668 PMCID: PMC6709307 DOI: 10.1097/MD.0000000000014955
Abstract
Background: The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk.
Methods: A comprehensive literature search was performed in PubMed and Web of Science databases through July 2018. A DerSimonian and Laird random-effects model was applied to calculate the pooled relative risk (RR) and its 95% confidence interval (CI).
Results: Eighteen cohort or nested case-control studies were included in this study with a total of 52,328 cases. In a random-effect pooled analysis, metformin use was not significantly associated with the risk of prostate cancer (RR 0.97, 95% CI 0.80-1.16, P = .711). Statistically significant heterogeneity was identified among included studies (P < .001, I = 98.1%). Sensitivity analysis indicated that no single study dominated the pooled RR.
Conclusion: The present large meta-analysis of cohort studies did not find an association between metformin use and prostate cancer risk.
Keywords: metformin, prostate cancer
Source: https://pubmed.ncbi.nlm.nih.gov/30896668/
Archive: https://archive.is/rZYad
